Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy
{{output}}
Importance: Voretigene neparvovec (VN) marketed as Luxturna (Novartis Europharm Ltd) is the first approved gene therapy for severe RPE65-related retinal dystrophy, showing low-luminance vision improvement in adult trials. Low-lum... ...
